The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of preoperative therapy for locally advanced thoracic esophageal cancer on the risk of perioperative complications: Results from multicenter phase III trial JCOG 1109.
 
Kazuo Koyanagi
No Relationships to Disclose
 
Ken Kato
Honoraria - Bristol-Myers Squibb; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Research Funding - Beigene (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst)
 
Yoshinori Ito
No Relationships to Disclose
 
Hiroyuki Daiko
No Relationships to Disclose
 
Soji Ozawa
No Relationships to Disclose
 
Takashi Ogata
No Relationships to Disclose
 
Hiroki Hara
No Relationships to Disclose
 
Takashi Kojima
Honoraria - Oncolys BioPharma; Ono Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Merck; MSD; Ono Pharmaceutical
Research Funding - Astellas Amgen BioPharama (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Tetsuya Abe
No Relationships to Disclose
 
Takeo Bamba
No Relationships to Disclose
 
Masaya Watanabe
No Relationships to Disclose
 
Hirofumi Kawakubo
No Relationships to Disclose
 
Yuichi Shibuya
No Relationships to Disclose
 
Yasuhiro Tsubosa
No Relationships to Disclose
 
Masahiro Tsuda
No Relationships to Disclose
 
Isao Nozaki
No Relationships to Disclose
 
Hideo Baba
Honoraria - Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); MSD K.K (Inst); Ono Pharmaceutical (Inst); Shin Nippon Biomedical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Ryunosuke Machida
No Relationships to Disclose
 
Haruhiko Fukuda
Honoraria - Chugai Pharma; Taiho Pharmaceutical
 
Yuko Kitagawa
Honoraria - Asahi Kasei; Astellas Pharma; Chugai Pharma; Dainippon Sumitomo Pharma; EA Pharma; Eisai; Kaken Pharmaceutical; Nihon Pharma; Ono Pharmaceutical; Otsuka; Otsuka; Sanofi; Shionogi; Taiho Pharmaceutical; Taisho Toyama Pharma; Yakult Honsha
Research Funding - Asahi Kasei (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); EA Pharma (Inst); Eisai (Inst); Kaken Pharmaceutical (Inst); Kyouwa Hakkou Kirin Co., Ltd. (Inst); Medicon (Inst); Nihon Pharma (Inst); Nippon Covidien (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Teijin Pharma (Inst); Toyama Chemical Co (Inst); TSUMURA & CO. (Inst); Yakult Honsha (Inst)